1 / 17

Novel pro-neurogenic compound that lowers synaptic

Novel pro-neurogenic compound that lowers synaptic A β 42 generation shows cognitive benefit and reduced hippocampal levels of insoluble and oligomeric A β 42 in vivo in an Alzheimer’s mouse model. Sam Gandy, M.D., Ph.D. Mount Sinai Chair in Alzheimer’s Disease Research

zihna
Download Presentation

Novel pro-neurogenic compound that lowers synaptic

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Novel pro-neurogenic compound that lowers synaptic Aβ42 generation shows cognitive benefit and reduced hippocampal levels of insoluble and oligomeric Aβ42 invivo in an Alzheimer’s mouse model Sam Gandy, M.D., Ph.D. Mount Sinai Chair in Alzheimer’s Disease Research Mount Sinai School of Medicine and James J Peters VA Medical Center in collaboration with BrainCells, Inc. Alzheimer’s Disease International March 8, 2012

  2. Baseline 78 wks Bapineuzumab Rx

  3. Might there be a safe and novel intervention that arrests progression of amyloidosis, enhances cognitive function, andstimulates hippocampal repair (neurogenesis)?

  4. Synaptic accumulation of Aβ42 is proposed to be a major mechanism in cause/progression of AD: Is metabotropic (mGluR) signaling involved in regulating Aβ42 metabolism at the synapse?

  5. “Synaptosome” or “synaptoneurosome”

  6. DCG-IV stimulates generation of Aβ42 but not Aβ40 Pretreatment with mGluR2/3 antagonist blocks DCG-IV stimulated generation of Aβ42

  7. Might there be a safe and novel intervention that arrests progression of amyloidosis,enhances cognitive function, andstimulates hippocampal repair (neurogenesis)?

  8. mGluR2/3 antagonist BCI-838 (632) reduces levels of various Aβconformers in hippocampus and cortex

  9. Might there be a safe and novel intervention that arrests progression of amyloidosis, enhances cognitive function, andstimulates hippocampal repair (neurogenesis)?

  10. mGluR2/3 antagonist BCI-838 (632) corrects Aβ-induced contextual memory deficits

  11. mGluR2/3 antagonist BCI-838 (632) improves novel object recognition, reduces anxiety in APP transgenic mice

  12. Might there be a safe and novel intervention that arrests progression of amyloidosis, enhances cognitive function, and stimulates hippocampal repair (neurogenesis)?

  13. mGluR2/3 antagonist BCI-838 (632)stimulates birth of new hippocampal neurons Black/brown specks are new hippocampal neurons born in response to BCI-838 therapy

  14. Summary mGluR2/3 antagonist BCI-838 (632) is an Aβ42-lowering pro-cognitive, and pro-neurogenic compound that may constitute a novel approach to early stages of Alzheimer’s disease that combines arrest of progression of amyloid pathology with stimulation of cognitive function and hippocampal repair (neurogenesis).

  15. John Steele Michelle Ehrlich Loren Khan Soong Ho Kim Justine Bonet

More Related